Lora D Weidner1,2, Pavitra Kannan3, Nicholas Mitsios2, Sun J Kang4, Matthew D Hall5, William H Theodore6, Robert B Innis1, Jan Mulder2. 1. Molecular Imaging Branch, National Institute of Mental Health, NIH, Bethesda, MD, USA. 2. Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden. 3. CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK. 4. Statistical Genomics and Data Analysis Core, National Institute of Mental Health, NIH, Bethesda, MD, USA. 5. Chemical Genomics Center, National Center for Advancing Translational Sciences, NIH, Bethesda, MD, USA. 6. Clinical Epilepsy Section, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.
Abstract
OBJECTIVE: The role of neuroinflammation in mesial temporal lobe epilepsy (MTLE), and how it relates to drug resistance, remains unclear. Expression levels of the inflammatory enzymes cyclooxygenase (COX)-1 and COX-2 have been found to be increased in animal models of epilepsy. Knowing the cellular expression of COX-1 and COX-2 is the key to understanding their functional role; however, only 3 studies have investigated COX-2 expression in epilepsy in humans, and there are no reports on COX-1. In addition, previous studies have shown that certain inflammatory proteins up-regulate ATP binding cassette (ABC) transporter expression (thought to be responsible for drug resistance), but this relationship remains unclear in human tissue. This study sought to measure the expression of COX-1, COX-2, and translocator protein 18 kDa (TSPO, an inflammation biomarker acting as a positive control), as well as ABC transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), in brain tissue samples from people with drug-resistant MTLE. METHODS: Formalin-fixed paraffin-embedded surgical brain tissue was obtained from 33 patients with drug-resistant MTLE. Multiplex immunofluorescence was used to quantify the expression and distribution of COX-1, COX-2, TSPO, P-gp, and BCRP. RESULTS: COX-1 was expressed in microglia, and COX-2 and TSPO were expressed in microglia and neurons. BCRP density correlated significantly with TSPO density, suggesting a potential relationship between inflammatory markers and efflux transporters. SIGNIFICANCE: To the best of our knowledge, this study is the first to measure the cellular expression of COX-1, COX-2, and TSPO in microglia, astrocytes, and neurons in surgical brain tissue samples from patients with drug-resistant MTLE. Further research is needed to determine the effects of the COX inflammatory pathway in epilepsy, and how it relates to the expression of the ABC transporters P-gp and BCRP. Wiley Periodicals, Inc.
OBJECTIVE: The role of neuroinflammation in mesial temporal lobe epilepsy (MTLE), and how it relates to drug resistance, remains unclear. Expression levels of the inflammatory enzymes cyclooxygenase (COX)-1 and COX-2 have been found to be increased in animal models of epilepsy. Knowing the cellular expression of COX-1 and COX-2 is the key to understanding their functional role; however, only 3 studies have investigated COX-2 expression in epilepsy in humans, and there are no reports on COX-1. In addition, previous studies have shown that certain inflammatory proteins up-regulate ATP binding cassette (ABC) transporter expression (thought to be responsible for drug resistance), but this relationship remains unclear in human tissue. This study sought to measure the expression of COX-1, COX-2, and translocator protein 18 kDa (TSPO, an inflammation biomarker acting as a positive control), as well as ABC transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), in brain tissue samples from people with drug-resistant MTLE. METHODS:Formalin-fixed paraffin-embedded surgical brain tissue was obtained from 33 patients with drug-resistant MTLE. Multiplex immunofluorescence was used to quantify the expression and distribution of COX-1, COX-2, TSPO, P-gp, and BCRP. RESULTS:COX-1 was expressed in microglia, and COX-2 and TSPO were expressed in microglia and neurons. BCRP density correlated significantly with TSPO density, suggesting a potential relationship between inflammatory markers and efflux transporters. SIGNIFICANCE: To the best of our knowledge, this study is the first to measure the cellular expression of COX-1, COX-2, and TSPO in microglia, astrocytes, and neurons in surgical brain tissue samples from patients with drug-resistant MTLE. Further research is needed to determine the effects of the COX inflammatory pathway in epilepsy, and how it relates to the expression of the ABC transporters P-gp and BCRP. Wiley Periodicals, Inc.
Authors: R B Banati; G W Goerres; R Myers; R N Gunn; F E Turkheimer; G W Kreutzberg; D J Brooks; T Jones; J S Duncan Journal: Neurology Date: 1999-12-10 Impact factor: 9.910
Authors: Paul Desjardins; Anny Sauvageau; Alain Bouthillier; Darren Navarro; Alan S Hazell; Christopher Rose; Roger F Butterworth Journal: Neurochem Int Date: 2003-03 Impact factor: 3.921
Authors: Vassilios Papadopoulos; Mario Baraldi; Tomás R Guilarte; Thomas B Knudsen; Jean-Jacques Lacapère; Peter Lindemann; Michael D Norenberg; David Nutt; Abraham Weizman; Ming-Rong Zhang; Moshe Gavish Journal: Trends Pharmacol Sci Date: 2006-07-05 Impact factor: 14.819
Authors: Eleonora Aronica; Jan A Gorter; Sandra Redeker; Erwin A van Vliet; Marja Ramkema; George L Scheffer; Rik J Scheper; Paul van der Valk; Sieger Leenstra; Johannes C Baayen; Wim G M Spliet; Dirk Troost Journal: Epilepsia Date: 2005-06 Impact factor: 5.864
Authors: Eleonora Aronica; Jan A Gorter; Marja Ramkema; Sandra Redeker; Filiz Ozbas-Gerçeker; Edwin A van Vliet; George L Scheffer; Rik J Scheper; Paul van der Valk; Johannes C Baayen; Dirk Troost; Filiz Ozbas-Gerçerer Journal: Epilepsia Date: 2004-05 Impact factor: 5.864
Authors: Björn Bauer; Anika M S Hartz; Anton Pekcec; Kathrin Toellner; David S Miller; Heidrun Potschka Journal: Mol Pharmacol Date: 2007-12-19 Impact factor: 4.436
Authors: Sanjay M Sisodiya; Lillian Martinian; George L Scheffer; Paul van der Valk; J Helen Cross; Rik J Scheper; Brian N Harding; Maria Thom Journal: Epilepsia Date: 2003-11 Impact factor: 5.864
Authors: Jeffrey H Meyer; Simon Cervenka; Min-Jeong Kim; William C Kreisl; Ioline D Henter; Robert B Innis Journal: Lancet Psychiatry Date: 2020-10-21 Impact factor: 27.083
Authors: Brad A Hobson; Douglas J Rowland; Sílvia Sisó; Michelle A Guignet; Zachary T Harmany; Suren B Bandara; Naomi Saito; Danielle J Harvey; Donald A Bruun; Joel R Garbow; Abhijit J Chaudhari; Pamela J Lein Journal: Toxicol Sci Date: 2019-08-01 Impact factor: 4.849
Authors: Anika M S Hartz; Ralf G Rempe; Emma L B Soldner; Anton Pekcec; Juli Schlichtiger; Richard Kryscio; Bjoern Bauer Journal: FASEB J Date: 2019-10-29 Impact factor: 5.834